Tìm theo
Boceprevir
Các tên gọi khác (2) :
  • SCH 503034
  • Victrelis
Thuốc Gốc
Small Molecule
CAS: 394730-60-0
ATC: J05AE12
CTHH: C27H45N5O5
PTK: 519.6767
Boceprevir is a direct acting protease inhibitor for the treatment of hepatitis C. It also has two isomers in which the S isomer is more active than the R-isomer. FDA approved on May 13, 2011.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C27H45N5O5
Phân tử khối
519.6767
Monoisotopic mass
519.342069575
InChI
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
InChI Key
InChIKey=LHHCSNFAOIFYRV-DOVBMPENSA-N
IUPAC Name
3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
Traditional IUPAC Name
boceprevir
SMILES
[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C
Độ hòa tan
2.34e-02 g/l
logP
1.78
logS
-4.3
pKa (strongest acidic)
12.44
pKa (Strongest Basic)
-0.91
PSA
150.7 Å2
Refractivity
138.2 m3·mol-1
Polarizability
56.55 Å3
Rotatable Bond Count
10
H Bond Acceptor Count
5
H Bond Donor Count
4
Physiological Charge
0
Number of Rings
3
Bioavailability
1
MDDR-Like Rule
true
Dược Lực Học : Telaprevir is a direct-acting antiviral agent (DAA) against the hepatitis C virus.
Cơ Chế Tác Dụng : Boceprevir is a direct acting protease inhibitor for the treatment of hepatitis C. It also has two isomers in which the S isomer is more active than the R-isomer. FDA approved on May 13, 2011. Boceprevir inhibits replication of the hepatitis C virus by binding reversibly to nonstructural protein 3/4a (NS3 and NS4A respectively) serine protease. NS4A is a cofactor that works with NS3 for viral replication.
Dược Động Học :
▧ Absorption :
Food increases exposure of boceprevir by up to 65% relative to fasting state. However, type of food and time of meal does not affect bioavailability of boceprevir and thus can be taken without regards to food. Tmax = 2 hours; Time to steady state, three times a day dosing = 1 day; Cmax, 400 mg single dose, healthy subject = 557 ng/mL; AUC ∞, healthy subject = 2020 ng · h/mL;
▧ Volume of Distribution :
~722 L
▧ Protein binding :
~75%
▧ Metabolism :
Hepatically metabolized by the aldo-ketoreductase pathway into inactive metabolites via reduction. To a lesser extent, CYP3A4 and CYP3A5 is also involved in the metabolism of boceprevir (oxidative process).
▧ Route of Elimination :
Removed via feces (79%) and urine (9%) which suggest some degree of hepatic excretion.
▧ Half Life :
Mean plasma half-life = 3.4 hours
▧ Clearance :
Mean total body clearance (Cl/F) = 161 L/h
Chỉ Định : Treatment of chronic hepatitis C genotype 1 in patients that have a compensated liver (as a result of liver diseases like cirrhosis) and are previously untreated or therapy with peginterferon alfa and ribavirin has failed.
Tương Tác Thuốc :
  • Alfuzosin Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
  • Atorvastatin Boceprevir increases the exposure of atorvastatin. Concomitant therapy should be closely monitored.
  • Carbamazepine Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
  • Cisapride Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
  • Conivaptan Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
  • Dihydroergotamine Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
  • Drospirenone Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
  • Etravirine The exposure of etravirine decreases whereas boceprevir's exposure increased. Therapeutic implications of this observation is unknown.
  • Fosphenytoin Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
  • Lomitapide Boceprevir increases levels of lomipatide by 27 folds by inhibiting CYP3A4 metabolism. Concomitant therapy of Boceprevir and strong CYP3A4 inhibitors (such as clarithromycin, conivaptan, indinavir, intraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, variconazole) with lomipatide is contraindicated.
  • Midazolam Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
  • Phenobarbital Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
  • Phenytoin Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
  • Pimozide Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
  • Ponatinib Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
  • Pravastatin Boceprevir increases pravastatin AUC by 60% with boceprevir. Concomitant therapy should be closely monitored.
  • Rifampicin Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
  • Sirolimus Boceprevir increases levels of sirolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring.
  • St. John's Wort Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated.
  • Tacrolimus Boceprevir increases levels of tacrolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring.
  • Tadalafil Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated.
Liều Lượng & Cách Dùng : Capsule - Oral - 200 mg
Dữ Kiện Thương Mại
Nhà Sản Xuất
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB08873
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D08876
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0085-0314-02
Wikipedia
http://en.wikipedia.org/wiki/Boceprevir
RxList
http://www.rxlist.com/victrelis-drug.htm
Drugs.com
http://www.drugs.com/cdi/boceprevir.html
... loading
... loading